8-KItem 8.01 · Other EventsItem 9.01 · Financial Statements
AbbVie Completes $10 Billion Debt Offering to Fund Apogee Acquisition
Filed with the SEC on · Summarized by InvestorsBot
On August 18, 2026, AbbVie completed a $10 billion offering of senior notes maturing from 2028 through 2066, with fixed interest rates ranging from 4.500% to 6.100% on most series. AbbVie expects to use the net proceeds to fund part of the cash consideration for its acquisition of Apogee Therapeutics, Inc., pay related costs and support general corporate purposes. If the Apogee deal is terminated or AbbVie abandons it, most of the notes would be subject to mandatory redemption at 101% of principal plus accrued interest, excluding the 2056 and 2066 notes.